92 related articles for article (PubMed ID: 11322639)
1. Inhibition of COX in ocular tissues: an in vitro model to identify selective COX-2 inhibitors.
García-Cabanes C; Palmero M; Bellot JL; Castillo M; Orts A
J Ocul Pharmacol Ther; 2001 Feb; 17(1):67-74. PubMed ID: 11322639
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
4. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
Giuliano F; Warner TD
Br J Pharmacol; 1999 Apr; 126(8):1824-30. PubMed ID: 10372826
[TBL] [Abstract][Full Text] [Related]
6. Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter.
Mastrangelo D; Wisard M; Rohner S; Leisinger H; Iselin CE
Urol Res; 2000 Dec; 28(6):376-82. PubMed ID: 11221916
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes.
Kato M; Nishida S; Kitasato H; Sakata N; Kawai S
J Pharm Pharmacol; 2001 Dec; 53(12):1679-85. PubMed ID: 11804398
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.
Elder DJ; Halton DE; Hague A; Paraskeva C
Clin Cancer Res; 1997 Oct; 3(10):1679-83. PubMed ID: 9815550
[TBL] [Abstract][Full Text] [Related]
9. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis.
Minter HA; Eveson JW; Huntley S; Elder DJ; Hague A
Clin Cancer Res; 2003 May; 9(5):1885-97. PubMed ID: 12738747
[TBL] [Abstract][Full Text] [Related]
10. The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition.
Xu H; Izon DJ; Loftin C; Spain LM
Cell Immunol; 2001 Dec; 214(2):184-93. PubMed ID: 12088417
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat.
Euchenhofer C; Maihófner C; Brune K; Tegeder I; Geisslinger G
Neurosci Lett; 1998 May; 248(1):25-8. PubMed ID: 9665655
[TBL] [Abstract][Full Text] [Related]
12. Kinetic basis for selective inhibition of cyclo-oxygenases.
Gierse JK; Koboldt CM; Walker MC; Seibert K; Isakson PC
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):607-14. PubMed ID: 10215599
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis.
Foitzik T; Hotz HG; Hotz B; Wittig F; Buhr HJ
Hepatogastroenterology; 2003; 50(52):1159-62. PubMed ID: 12846004
[TBL] [Abstract][Full Text] [Related]
14. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition.
Totzke G; Schulze-Osthoff K; Jänicke RU
Oncogene; 2003 Sep; 22(39):8021-30. PubMed ID: 12970750
[TBL] [Abstract][Full Text] [Related]
16. Development of an in-vitro test system for the evaluation of cyclooxygenase-2 inhibitors.
Laufer S; Zechmeister P; Klein T
Inflamm Res; 1999 Mar; 48(3):133-8. PubMed ID: 10219655
[TBL] [Abstract][Full Text] [Related]
17. Selective COX-2 inhibitor, NS-398, inhibits the replicative senescence of cultured dermal fibroblasts.
Han JH; Roh MS; Park CH; Park KC; Cho KH; Kim KH; Eun HC; Chung JH
Mech Ageing Dev; 2004 May; 125(5):359-66. PubMed ID: 15130753
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells.
Sun Y; Tang XM; Half E; Kuo MT; Sinicrope FA
Cancer Res; 2002 Nov; 62(21):6323-8. PubMed ID: 12414664
[TBL] [Abstract][Full Text] [Related]
19. NS-398 and piroxicam suppress UVB-induced activator protein 1 activity by mechanisms independent of cyclooxygenase-2.
Liu G; Ma WY; Bode AM; Zhang Y; Dong Z
J Biol Chem; 2003 Jan; 278(4):2124-30. PubMed ID: 12433932
[TBL] [Abstract][Full Text] [Related]
20. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes.
Blanco FJ; Guitian R; Moreno J; de Toro FJ; Galdo F
J Rheumatol; 1999 Jun; 26(6):1366-73. PubMed ID: 10381057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
